Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $15 from $10 and keeps a Buy rating on the shares. While the firm typically waits for acquisitions to close before updating its numbers, Craig-Hallum is doing so prior to close as it is clear investors are getting excited about the profile of Eton post-acquisition. The firm is also very confident in this deal closing, leading to its confidence in updating numbers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ETON:
- Eton Pharmaceuticals price target raised to $11 from $9 at H.C. Wainwright
- Eton Pharmaceuticals price target raised to $10 from $8 at Craig-Hallum
- Eton Pharmaceuticals to acquire Increlex from Ipsen
- Biotech Alert: Searches spiking for these stocks today
- Eton Pharmaceuticals assumed with a Buy at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
